Corporate and regulatory developments over the Christmas period
On the corporate front Astellas continued to buy, while Qiagen decided that it was not, after all, up for sale.
Why a 2020 spotlight will fall on tafasitamab
The anti-CD19 MAb is Morphosys’s lead pipeline asset, and an imminent filing could see it approved next year.
Bloated on arrival? Biotech's weightiest new issues
A big valuation at float is no guarantee of ongoing investor support, as a look at the sector’s biggest IPOs reveals.
Sanofi does a spring clean
The French company has taken a look at its R&D portfolio, and made some radical changes in oncology and diabetes.
Crenezumab flop makes Biogen bulls a little more nervous
One day after Biogen expands aducanumab trials, a canary in the coal mine, the rival crenezumab, fails in phase III.
The most disputed sales outlooks in biopharma
Celgene’s Revlimid ranks as biopharma’s most contested blockbuster, with a huge spread in future sales forecasts, while drugs from Bristol-Myers Squibb and Sanofi also…
AAIC event – Biogen and Eisai move to consolidate beta-amyloid lead
Two weeks ago BAN2401 was hailed as a possible disease-modifying Alzheimer's drug. Full data at the AAIC meeting to will show whether or not this is was all hype.
Why Immatics could soon become the next listed cell therapy player
Immunocore and Adaptimmune could shortly have a publicly listed rival.
